Overview

Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In Western industrialized countries, endometrial cancer is the most common malignancy of the female reproductive tract. The general therapy options are surgery, radiotherapy, chemotherapy and endocrine therapy. This trial will investigate the efficacy and safety of letrozole in the treatment of advanced or recurrent hormone receptor-positive endometrial cancer .
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Hormones
Letrozole